Bausch + Lomb (BLCO)

The company operates through three main segments. Its Vision Care business includes contact lenses and lens care products, along with consumer eye health brands such as Biotrue and Lumify. This segment serves everyday needs ranging from vision correction to dry eye relief and redness reduction, and it benefits from repeat consumer purchasing patterns. The Surgical segment provides products used in cataract, refractive, and vitreoretinal procedures, including intraocular lenses, surgical instruments, and equipment used by eye surgeons. The Ophthalmic Pharmaceuticals segment markets prescription products that treat a range of eye conditions, including inflammation, glaucoma, retinal disease, and post-surgical complications.

Bausch + Lomb’s competitive position is built on brand recognition, relationships with eye care professionals, a large installed product base, and a portfolio that reaches both clinical and consumer channels. The company participates in markets influenced by aging demographics, increased screen use, rising demand for vision correction, and continued innovation in cataract and eye disease treatment.

For investors, BLCO offers exposure to a diversified eye care platform rather than a single product category. Its results depend on product launches, prescription trends, surgical procedure volumes, contact lens demand, reimbursement conditions, and competition from other global healthcare and medical technology companies.